-
1h 3m 31s
-
1h 12m 7s
-
36m 57s
-
51m 18s
-
52m 44s
-
58m 38s
Presentations
- Assessing Ventricular Function in Cardiomyopathy Diagnosis
- Beyond Imaging: Diagnostic Tools for Cardiomyopathy
- Precision Diagnosis: The Role of Phenotyping in Cardiomyopathy
Radcliffe Cardiology was proud to host New Horizons in Cardiomyopathy 2025 (NHC), specially focused on cardiac amyloidosis and cardiomyopathy diagnosis and treatment.
Day 1 focused on hypertrophic cardiomyopathy (HCM), with a detailed exploration of HCM and an emphasis on emerging therapies and management strategies. Day 2 focused on amyloidosis, providing a comprehensive update on the diagnosis and treatment of cardiac amyloidosis, along with insights into the latest research and clinical practices.
The course directors, Prof Rodney Falk (Brigham and Women’s Hospital, US), Prof Perry Elliott (University College London, UK), and Prof Marianna Fontana (University College London, UK), led a distinguished group of faculty members who are renowned experts in the field of cardiac amyloidosis and HCM.
NHC was designed to educate healthcare professionals on the evolving management practices in cardiac amyloidosis and cardiomyopathy in an informal and engaging learning environment featuring thought-provoking presentations, cases and practical masterclasses.
*Please note, the live version of New Horizons in Cardiomyopathy was accredited. The on-demand version is not.
Learning Objectives
- Increase the awareness of at-risk patients
- Improve understanding of screening procedures
- Provide guidance on the use of imaging for diagnosis
- Improve awareness on current and emerging treatment
- Provide guidance on initiating treatment and managing comorbidities
Target Audience
- Cardiologists (device implanters, heart failure)
- Imaging Specialists
- Electrophysiologists
- Primary Care
- Haematologists
- Cardiac Nurse Practitioners
More from this programme
Part 1
Day 1: Session 1 – The Cardiomyopathy Mindset
In this opening session of NHC, presentations cover the basics of cardiomyopathy diagnosis, including when to suspect it and overview of the diagnostic pathway. The faculty present on clinical indicators for suspicion and discuss case studies.
Part 2
Day 1: Session 2 – The Diagnostic Pathway
Session 2 focuses on the diagnostic pathway. Faculty discuss assessing the ventricular function in the diagnosis of cardiomyopathy, diagnostic tools and phenotyping.
| 1 session | |
| Watch now |
Part 3
Day 1: Session 3 – The Management of Cardiomyopathy
This session highlights the critical role of risk stratification and prognostic assessment in the management of hypertrophic cardiomyopathy. The discussion also delves into the management strategies tailored to hypertrophic cardiomyopathy patients through a case study approach.
Part 4
Day 2: Session 1 – Amyloidosis Specific Diagnosis
This session covers amyloidosis diagnosis, featuring a case study on key clinical clues. It explores scintigraphy challenges and CMR imaging's role in cardiac amyloidosis.
Part 5
Day 2: Session 2 – Implementation in Practice
The faculty dive into a complex case, examining the challenges of both diagnosing and managing a patient, providing valuable insights into navigating such multifaceted scenarios.
Part 6
Day 2: Session 3 – Phenotyping Management Strategies
This session focuses on phenotyping management strategies for amyloidosis. The faculty discuss collaborating with haematologists to address cardiac complexities and complications that arise during chemotherapy.
Part 7
Day 2: Session 4 – The Treatment Horizon
In the final session of the event, faculty provide an overview of recently completed and on-going trials.
| 1 session | |
| Watch now |
Faculty Biographies
Marianna Fontana
Professor of Cardiology and Honorary Consultant Cardiologist
Prof Marianna Fontana is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, London, UK.
Her main clinical and research interests include the delivery of efficient and effective care for patients with amyloidosis, with a particular focus on new technologies.
Perry Elliott
Professor in Inherited Cardiovascular Disease
Personal History
Professor Perry Mark Elliott was born on December 7, 1963, in London.6 He is a Professor of Cardiovascular Medicine at University College London (UCL) and a Senior Investigator of the UK National Institute for Health Research (NIHR).
He is Director of the UCL Centre for Heart Muscle Disease, Head of Clinical Research at the Institute of Cardiovascular Science UCL and a consultant cardiologist in the Centre for Inherited Cardiovascular Disease at the Barts Heart Centre, St. Bartholomew's Hospital London, UK.3
Academic History1
Dr Elliott studied medicine at St. Thomas’s Hospital Medical School, London from 1982 to 1987.
After graduating in 1987 he trained in general medicine. In 1991 he became a member of the Royal College of Physicians and completed his general cardiology training at St. George’s Hospital Medical School, London.
His…
Ahmad Masri
Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.
He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.
Caroline Coats
Honorary Clinical Senior Lecturer
Dr Caroline Coats is an Honorary Clinical Senior Lecturer at the University of Glasgow, Glasgow, UK.
Dr Coats leads the West of Scotland Inherited Cardiac Conditions Service. She was awarded a Career Researcher Fellowship from the Chief Scientific Office and serves as Principal Investigator for several global clinical trials.
Victoria Delgado
Cardiologist and Assistant Professor of Cardiology
Dr Victoria Delgado is a board certified cardiologist with specific expertise in multimodality imaging, Assistant professor of Cardiology at the Leiden University Medical Center. For the past 13 years, she has been actively performing research in the field of cardiac mechanics and underlying pathophysiological mechanisms of heart failure in various cardiac diseases, particularly in valvular heart disease and coronary artery disease.
Victoria has been board member of the European Association of Cardiovascular Imaging (councillor and chair of scientific documents), task force member of the European Society of Cardiology (ESC) Guidelines, member of the ESC Guidelines committee and Congress Programme Committee and currently ESC board member. Furthermore, she is an associate editor of Circulation and Journal of American Society of Echocardiography.